Effectiveness of Multimodal Physical Therapy in Migraine
MIGPHYSTREAT
1 other identifier
interventional
36
1 country
1
Brief Summary
INTRODUCTION: It is very common that migraine patients could refer neck pain during or after the pain phase of migraine, suggesting that migraine pathophysiological mechanisms could be effective in activating neck pain pathways and be part of the migraine attack. Due to the therapeutic effect of multimodal physical therapy (mobilization and/or manipulation plus exercises) on several pain conditions arising from articular and/or muscular structures such as neck pain, and given the close clinical, anatomical and pathogenetic bi-directional relationship between neck pain and migraine, it would be of interest to evaluate the effectiveness of the physical treatment of the neck region in migraine pain. PURPOSE: to evaluate the efficacy of a combined multimodal physical therapy approach plus usual care vs. usual care alone in subjects with episodic and chronic migraine with concomitant cervical musculoskeletal dysfunctions. STUDY DESIGN: this is a prospective, parallel group, randomized clinical trial. METHODS: A total of 56 subjects aged 18-65 who meet criteria for episodic or chronic migraine with concomitant cervical musculoskeletal dysfunctions will be randomly assigned to receive, musculoskeletal focused multimodal physical therapy (16 sessions over 8 weeks) plus usual care treatment vs. usual care alone. CONFLICT OF INTEREST: not declared.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 11, 2022
CompletedFirst Posted
Study publicly available on registry
February 7, 2022
CompletedStudy Start
First participant enrolled
February 24, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2025
CompletedFebruary 28, 2024
February 1, 2024
2.8 years
January 11, 2022
February 27, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change in screening period monthly migraine days at the end of the intervention period (week 20) and at the end of the study (week 28) (daily migraine report)
Number of monthly migraine days
At the end of the 12-week screening period (week 12), at the end of the 8-week intervention period (week 20), and at the end of the study 8 weeks after the last treatment (week 28)
Change in screening period monthly migraine days with use of acute medication at the end of the intervention period (week 20) and at the end of the study (week 28) (daily migraine report)
Monthly migraine days with use of acute medication
At the end of the 12-week screening period (week 12), at the end of the 8-week intervention period (week 20), and at the end of the study 8 weeks after the last treatment (week 28)
Secondary Outcomes (3)
Change in screening period Migraine Disability Assessment Score (MIDAS) at the end of the intervention period (week 20) and at the end of the study (week 28)
At the end of the 12-week screening period (week 12), at the end of the 8-week intervention period (week 20), and at the end of the study 8 weeks after the last treatment (week 28)
Change in screening period Neck disability index (NDI) at the end of the intervention period (week 20) and at the end of the study (week 28)
At the end of the 12-week screening period (week 12), at the end of the 8-week intervention period (week 20), and at the end of the study 8 weeks after the last treatment (week 28)
Change in screening period Patient Health Questionnaire-9 (PHQ-9) at the end of the intervention period (week 20) and at the end of the study (week 28)
At the end of the 12-week screening period (week 12), at the end of the 8-week intervention period (week 20), and at the end of the study 8 weeks after the last treatment (week 28)
Study Arms (2)
Multimodal Physical therapy approach plus usual care
ACTIVE COMPARATORHVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
Usual care
NO INTERVENTIONStandard pharmacological treatment alone
Interventions
HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
Standard pharmacological treatment alone.
Eligibility Criteria
You may qualify if:
- patients aged 18-65 years;
- patients with episodic migraine with and without aura (experiencing 6-14 days/month with migraine);
- patients with chronic migraine;
- patients who achieved \>30% \<50% reduction from their individual baseline in the number of monthly migraine days on therapy with standard stable pharmacological treatments during the past 3 months;
- concomitant cervical dysfunctions.
You may not qualify if:
- self-report of neck injury/trauma;
- acute radiculopathy;
- history of carotid or vertebral artery dissection;
- stroke;
- cervical/cranial nerve block in the past three months;
- pregnancy;
- history of infection;
- migraine attack during the assessment;
- diagnosis of other concomitant headaches (such as cervicogenic headache, tension-type headache, cluster headache, medication overuse headache);
- having received physical treatment in the past three months or botulinum toxin in the past six months;
- any unstable medical o psychiatric condition.
- history of any other rheumatic or chronic diseases such as fibromyalgia;
- neuralgias, or self-report of vestibular disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Neuromed IRCCSlead
Study Sites (1)
IRCCS Neuromed
Pozzilli, Isernia, 86077, Italy
Related Publications (5)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. No abstract available.
PMID: 29368949BACKGROUNDAshina S, Bendtsen L, Lyngberg AC, Lipton RB, Hajiyeva N, Jensen R. Prevalence of neck pain in migraine and tension-type headache: a population study. Cephalalgia. 2015 Mar;35(3):211-9. doi: 10.1177/0333102414535110. Epub 2014 May 22.
PMID: 24853166BACKGROUNDFlorencio LL, Chaves TC, Carvalho GF, Goncalves MC, Casimiro EC, Dach F, Bigal ME, Bevilaqua-Grossi D. Neck pain disability is related to the frequency of migraine attacks: a cross-sectional study. Headache. 2014 Jul-Aug;54(7):1203-10. doi: 10.1111/head.12393. Epub 2014 May 26.
PMID: 24863346BACKGROUNDLuedtke K, Starke W, May A. Musculoskeletal dysfunction in migraine patients. Cephalalgia. 2018 Apr;38(5):865-875. doi: 10.1177/0333102417716934. Epub 2017 Jun 22.
PMID: 28641450BACKGROUNDBartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts and synthesis. Curr Pain Headache Rep. 2003 Oct;7(5):371-6. doi: 10.1007/s11916-003-0036-y.
PMID: 12946290BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Armando Perrotta, MD
Neuromed IRCCS
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, INVESTIGATOR
- Masking Details
- Physiotherapists are blinded toward the diagnosis and outcome measures.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 11, 2022
First Posted
February 7, 2022
Study Start
February 24, 2022
Primary Completion
December 1, 2024
Study Completion
May 1, 2025
Last Updated
February 28, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share